We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
-2.2%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.47B
AUM Growth
-$30.5M
Cap. Flow
+$92.4M
Cap. Flow %
6.31%
Top 10 Hldgs %
63.82%
Holding
43
New
4
Increased
16
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$53.2M
2
CATX icon
Perspective Therapeutics
CATX
+$36.9M
3
ALKS icon
Alkermes
ALKS
+$33.7M
4
PCVX icon
Vaxcyte
PCVX
+$30.3M
5
COGT icon
Cogent Biosciences
COGT
+$25.1M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$56.2M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$54.5M
3
VERA icon
Vera Therapeutics
VERA
+$27.4M
4
KYTX icon
Kyverna Therapeutics
KYTX
+$22.7M
5
ENGN icon
enGene Therapeutics
ENGN
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
2 Financials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$189M 12.92%
3,200,000
-1,160,000
-27% -$56.2M
NUVL
2
DELISTED
Nuvalent
NUVL
$113M 7.7%
1,487,756
– –
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.32B
$107M 7.33%
2,754,266
+586,473
+27% +$23.4M
PCVX icon
4
Vaxcyte
PCVX
$7.89B
$98.5M 6.73%
1,305,000
+445,000
+52% +$30.3M
ELVN icon
5
Enliven Therapeutics
ELVN
$3.78B
$92.9M 6.34%
3,973,245
– –
VERA icon
6
Vera Therapeutics
VERA
$2.54B
$89.5M 6.11%
2,475,000
-690,000
-22% -$27.4M
COGT icon
7
Cogent Biosciences
COGT
$6.79B
$82.1M 5.6%
9,738,000
+3,313,000
+52% +$25.1M
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$58.1M 3.97%
1,425,000
+1,255,467
+741% +$53.2M
CLDX icon
9
Celldex Therapeutics
CLDX
$2.77B
$52.7M 3.6%
1,425,000
+558,532
+64% +$21.1M
DFTX
10
Definium Therapeutics
DFTX
$5.73B
$51.5M 3.52%
7,145,888
+1,312,555
+23% +$11.5M
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$7B
$50.3M 3.43%
1,225,000
+175,000
+17% +$6.99M
ARVN icon
12
Arvinas
ARVN
$518M
$50.2M 3.42%
1,884,361
+609,361
+48% +$19.4M
SYRE icon
13
Spyre Therapeutics
SYRE
$8.87B
$46.7M 3.19%
1,988,084
+104,000
+6% +$3.51M
CATX icon
14
Perspective Therapeutics
CATX
$332M
$46.4M 3.17%
4,657,345
+2,552,082
+121% +$36.9M
PHVS icon
15
Pharvaris
PHVS
$2.39B
$34M 2.32%
1,810,175
+85,175
+5% +$1.73M
ALKS icon
16
Alkermes
ALKS
$8.82B
$33.1M 2.26%
+1,375,000
New +$33.7M
VRDN icon
17
Viridian Therapeutics
VRDN
$2.13B
$32.9M 2.25%
2,528,032
+593,379
+31% +$8.21M
KURA icon
18
Kura Oncology
KURA
$922M
$32.8M 2.24%
1,593,350
+68,350
+4% +$1.4M
NKTX icon
19
Nkarta
NKTX
$162M
$24.5M 1.67%
4,151,034
+986,034
+31% +$6.98M
CELC icon
20
Celcuity
CELC
$4.03B
$24M 1.64%
1,464,105
-91,849
-6% -$1.54M
THRD
21
DELISTED
Third Harmonic Bio
THRD
$20.1M 1.37%
1,545,426
+295,426
+24% +$3.65M
IMVT icon
22
Immunovant
IMVT
$8.09B
$19.8M 1.35%
750,990
– –
ABVX
23
Abivax
ABVX
$11B
$17M 1.16%
1,284,110
-610,893
-32% -$8.74M
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.84B
$16.9M 1.16%
825,000
+506,149
+159% +$10.6M
CCCC icon
25
C4 Therapeutics
CCCC
$376M
$15.8M 1.08%
3,410,384
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Commodore Capital held 43 positions worth $1.47B, down 2% from $1.5B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Commodore Capital deployed $92.4M of net new capital in Q2 2024, opening 4 new positions and adding to 16 existing holdings. Its largest new stake was Alkermes: 1,375,000 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Merus, an estimated $56.2M trimmed.

  • Commodore Capital's largest Q2 2024 buy was Alkermes: 1,375,000 shares worth $33.1M.
  • Commodore Capital added most to Soleno Therapeutics in Q2 2024, an estimated $53.2M increase.
  • Commodore Capital's biggest Q2 2024 reduction was Merus, cutting an estimated $56.2M.
  • Commodore Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $54.5M.
  • Commodore Capital's ten largest holdings make up 64% of its $1.47B portfolio in Q2 2024.
  • Commodore Capital opened 4 new positions and closed 8 in Q2 2024.
  • Commodore Capital's portfolio value fell 2% quarter-over-quarter to $1.47B.

Based on Commodore Capital's 13F filing for Q2 2024, filed 14 Aug 2024.